Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

siRNA - Small Interfering RNAs

siRNA - Small Interfering RNAs

Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the ATP-dependent...

RNA Interference

RNA Interference

RNA interference (RNAi) is a process in which a small non-coding RNA molecule blocks the post-transcriptional expression of a gene by binding to its messenger RNA (mRNA) and preventing the protein from being translated.
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...

Experimental RNAi

Experimental RNAi

RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...

Small interfering RNAs (siRNA)

Small interfering RNAs (siRNA)

Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the ATP-dependent...

Nucleic Acid Structure

Nucleic Acid Structure

The pentose sugar in DNA is deoxyribose, while in RNA the pentose sugar is ribose. The difference between the sugars is the presence of the hydroxyl group on the ribose's second carbon and a hydrogen on the deoxyribose's second carbon. The phosphate residue attaches to the hydroxyl group of the 5′ carbon of one sugar and the hydroxyl group of the 3′ carbon of the sugar of the next nucleotide, which forms a 5′ to 3′ phosphodiester linkage.
DNA Structure
DNA has a double-helix structure. The...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Durvalumab with carboplatin/paclitaxel and bevacizumab followed by durvalumab and bevacizumab with or without olaparib maintenance in newly diagnosed non-BRCA-mutated advanced ovarian cancer.

Annals of oncology : official journal of the European Society for Medical Oncology·2025

Same author

Sex-Specific Skeletal Muscle Gene Expression Responses to Exercise Reveal Novel Direct Mediators of Insulin Sensitivity Change.

medRxiv : the preprint server for health sciences·2024

Same author

Niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer: final overall survival results from the PRIMA/ENGOT-OV26/GOG-3012 trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2024

Same author

Maintenance olaparib rechallenge in patients with platinum-sensitive relapsed ovarian cancer previously treated with a PARP inhibitor (OReO/ENGOT-ov38): a phase IIIb trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2023

Same author

Association of location of BRCA1 and BRCA2 mutations with benefit from olaparib and bevacizumab maintenance in high-grade ovarian cancer: phase III PAOLA-1/ENGOT-ov25 trial subgroup exploratory analysis.

Annals of oncology : official journal of the European Society for Medical Oncology·2022

Same author

Depression and anxiety in women with malignant ovarian germ cell (MOGCT) and sex cord stromal tumors (SCST): an analysis of the AGO-CORSETT database.

Archives of gynecology and obstetrics·2022

Search research articles

Related Experiment Video

Updated: Jul 17, 2026

Delivery of Therapeutic siRNA to the CNS Using Cationic and Anionic Liposomes

Delivery of Therapeutic siRNA to the CNS Using Cationic and Anionic Liposomes

Published on: July 23, 2016

A non-covalent peptide-based strategy for siRNA delivery.

L Crombez¹, A Charnet, M C Morris

¹Centre de Recherches de Biochimie Macromoléculaire, CRBM-CNRS, Department of Molecular Biophysics and Therapeutics, 1919 Route de Mende, 34293 Montpellier, France.

Biochemical Society Transactions

|January 20, 2007

Summary

A novel MPG peptide strategy effectively delivers short interfering RNAs (siRNAs) by forming nanoparticles. This approach enhances cellular uptake and bioavailability for potential therapeutic applications in vivo.

More Related Videos

Porous Silicon Microparticles for Delivery of siRNA Therapeutics

Porous Silicon Microparticles for Delivery of siRNA Therapeutics

Published on: January 15, 2015

Synthesis, Functionalization, and Characterization of Fusogenic Porous Silicon Nanoparticles for Oligonucleotide Delivery

Synthesis, Functionalization, and Characterization of Fusogenic Porous Silicon Nanoparticles for Oligonucleotide Delivery

Published on: April 16, 2019

Related Experiment Videos

Last Updated: Jul 17, 2026

Delivery of Therapeutic siRNA to the CNS Using Cationic and Anionic Liposomes

Delivery of Therapeutic siRNA to the CNS Using Cationic and Anionic Liposomes

Published on: July 23, 2016

Porous Silicon Microparticles for Delivery of siRNA Therapeutics

Porous Silicon Microparticles for Delivery of siRNA Therapeutics

Published on: January 15, 2015

Synthesis, Functionalization, and Characterization of Fusogenic Porous Silicon Nanoparticles for Oligonucleotide Delivery

Synthesis, Functionalization, and Characterization of Fusogenic Porous Silicon Nanoparticles for Oligonucleotide Delivery

Published on: April 16, 2019

Area of Science:

Biotechnology
Molecular Biology
Drug Delivery Systems

Background:

Clinical development of short interfering RNAs (siRNAs) is hindered by poor cellular uptake and bioavailability.
Existing viral and non-viral delivery methods face significant challenges for in vivo applications.

Purpose of the Study:

To introduce and evaluate a novel delivery strategy for siRNAs using an amphipathic peptide, MPG.
To demonstrate the efficiency of MPG-based nanoparticles for siRNA delivery in vitro and in vivo.

Main Methods:

Development of stable nanoparticles by complexing siRNA with the MPG peptide.
Assessment of cellular uptake mechanisms, bypassing the endosomal pathway.
Evaluation of siRNA delivery efficiency in various cell lines and in animal models.

Main Results:

MPG peptide forms stable nanoparticles with siRNA, enhancing cellular internalization.
MPG-based particles facilitate endosomal escape for efficient siRNA delivery.
Successful delivery of biologically active siRNA in diverse cell lines and in vivo models.

Conclusions:

The MPG peptide represents a potent and effective non-viral strategy for siRNA delivery.
MPG-based nanoparticles overcome key limitations in siRNA bioavailability and cellular uptake.
This strategy holds promise for advancing nucleic acid-based therapeutics in clinical settings.